Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 06
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
PDS Biotechnology Corp
PDSB
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.20
0.45
60.32%
Ult. Agg.: Oct 6, 9:08 AM
$1.22
0.47
62.99%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
PDS Biotechnology Analyst Price Targets - Benzinga
PDS Biotechnology Analyst Price Targets
Wall Street analyst price targets and consensus rating for PDS Biotechnology (PDSB).
Analyst Ratings News
PRO
HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $5
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $7 to $5.
Benzinga Newsdesk
PRO
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $7 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $7 price target.
Benzinga Newsdesk
PRO
HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $7
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $15 to $7.
Benzinga Newsdesk
PRO
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $15 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $15 price target.
Benzinga Newsdesk
PRO
B. Riley Securities Maintains Buy on PDS Biotechnology, Lowers Price Target to $3
B. Riley Securities analyst Kalpit Patel maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $5 to $3.
Benzinga Newsdesk
PRO
HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Raises Price Target to $15
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $13 to $15.
Benzinga Newsdesk
Crea una watchlist
GRATIS: Segui le azioni e criptovalute con le migliori notifiche di internet
Clicca per iniziare
People Also Watch
AbbVie Inc
NYSE:ABBV
$265.64
-0.05%
Amgen Inc
NASDAQ:AMGN
$405.44
-%
Gilead Sciences Inc
NASDAQ:GILD
$144.67
0.03%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
$501.06
-0.49%
Moderna Inc
NASDAQ:MRNA
$201.22
-0.99%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
$726
-0.06%
Natera Inc
NASDAQ:NTRA
$429.97
1.01%
argenx SE
NASDAQ:ARGX
$920.23
0.8%
Revolution Medicines Inc
NASDAQ:RVMD
$209.77
1%
BeOne Medicines Ltd
NASDAQ:ONC
$364.8
0.86%
Mostra tutte le 10 aziende correlate
